For the quarter ending 2026-03-31, TTRX had $6,141,527 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | -970,972 | 279,070 | -3,473,150 |
| Depreciation and amortization | - | 52,746 | - |
| Amortization expense | -24,140 | - | 38,591 |
| Stock-based compensation expense | 280,830 | 256,380 | 162,865 |
| Non-cash operating lease expense | - | 1,172 | - |
| Common stock issued in exchange for services | - | 0 | 250,000 |
| Net gain from change in fair value of derivative liability instruments | 697,561 | 2,574,971 | - |
| Gain from change in fair value of forward contract liability | - | -380,442 | - |
| Non-cash operating lease effect | - | - | 1,165 |
| Amortization of deferred offering cost | 477,647 | 496,948 | - |
| Prepaids and other current assets | 123,738 | -68,283 | -36,742 |
| Accounts payable and accrued expenses | -613,464 | 664,303 | 1,597,153 |
| Net cash used in operating activities | -1,632,807 | -1,176,267 | -1,386,634 |
| Purchases of intangible assets | 12,227 | 31,441 | 121,545 |
| Net cash used in investing activities | -12,227 | -31,441 | -121,545 |
| Cash receipt from stock subscription receivable | 1,070,000 | - | - |
| Proceeds from issuance of stock, net of issuance costs | - | 3,177,696 | 3,741,736 |
| Proceeds from avenue capital loan agreement | 6,716,561 | - | - |
| Net cash provided by financing activities | 7,786,561 | 3,177,696 | 3,741,736 |
| Net increase (decrease) in cash and cash equivalents | 6,141,527 | 1,969,988 | 2,233,557 |
| Cash and cash equivalents at beginning of the period | 5,076,144 | 3,106,156 | 872,599 |
| Cash and cash equivalents at end of the period | 11,217,671 | 5,076,144 | 3,106,156 |
Turn Therapeutics Inc. (TTRX)
Turn Therapeutics Inc. (TTRX)